vs
派安盈（PAYO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
派安盈的季度营收约是Ultragenyx Pharmaceutical Inc.的1.0倍（$217.0M vs $207.3M），派安盈净利率更高（8.8% vs -62.0%，领先70.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.5%），派安盈自由现金流更多（$40.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 16.3%）
派安盈（Payoneer）是一家美国金融服务企业，主要为全球用户提供在线跨境汇款、数字支付解决方案及营运资金支持，助力中小企业、跨境电商及自由职业者高效处理全球收付款业务，降低跨境资金流转成本。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PAYO vs RARE — 直观对比
营收规模更大
PAYO
是对方的1.0倍
$207.3M
营收增速更快
RARE
高出16.4%
9.5%
净利率更高
PAYO
高出70.8%
-62.0%
自由现金流更多
PAYO
多$141.1M
$-100.8M
两年增速更快
RARE
近两年复合增速
16.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $217.0M | $207.3M |
| 净利润 | $19.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 13.3% | -54.7% |
| 净利率 | 8.8% | -62.0% |
| 营收同比 | 9.5% | 25.9% |
| 净利润同比 | 4.5% | 3.5% |
| 每股收益（稀释后） | $0.05 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PAYORARE
| Q4 25 | $217.0M | $207.3M | ||
| Q3 25 | $209.7M | $159.9M | ||
| Q2 25 | $200.5M | $166.5M | ||
| Q1 25 | $186.3M | $139.3M | ||
| Q4 24 | $198.2M | $164.6M | ||
| Q3 24 | $180.4M | $139.5M | ||
| Q2 24 | $171.2M | $147.0M | ||
| Q1 24 | $160.5M | $108.8M |
净利润PAYORARE
| Q4 25 | $19.0M | $-128.6M | ||
| Q3 25 | $14.1M | $-180.4M | ||
| Q2 25 | $19.5M | $-115.0M | ||
| Q1 25 | $20.6M | $-151.1M | ||
| Q4 24 | $18.2M | $-133.2M | ||
| Q3 24 | $41.6M | $-133.5M | ||
| Q2 24 | $32.4M | $-131.6M | ||
| Q1 24 | $29.0M | $-170.7M |
营业利润率PAYORARE
| Q4 25 | 13.3% | -54.7% | ||
| Q3 25 | 17.3% | -106.9% | ||
| Q2 25 | 15.0% | -64.8% | ||
| Q1 25 | 15.7% | -102.6% | ||
| Q4 24 | 14.7% | -74.3% | ||
| Q3 24 | 19.5% | -94.6% | ||
| Q2 24 | 27.0% | -79.1% | ||
| Q1 24 | 23.9% | -151.9% |
净利率PAYORARE
| Q4 25 | 8.8% | -62.0% | ||
| Q3 25 | 6.7% | -112.8% | ||
| Q2 25 | 9.7% | -69.0% | ||
| Q1 25 | 11.0% | -108.5% | ||
| Q4 24 | 9.2% | -80.9% | ||
| Q3 24 | 23.1% | -95.7% | ||
| Q2 24 | 18.9% | -89.5% | ||
| Q1 24 | 18.1% | -156.8% |
每股收益（稀释后）PAYORARE
| Q4 25 | $0.05 | $-1.28 | ||
| Q3 25 | $0.04 | $-1.81 | ||
| Q2 25 | $0.05 | $-1.17 | ||
| Q1 25 | $0.05 | $-1.57 | ||
| Q4 24 | $0.03 | $-1.34 | ||
| Q3 24 | $0.11 | $-1.40 | ||
| Q2 24 | $0.09 | $-1.52 | ||
| Q1 24 | $0.08 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $415.5M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $704.4M | $-80.0M |
| 总资产 | $9.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PAYORARE
| Q4 25 | $415.5M | $421.0M | ||
| Q3 25 | $479.4M | $202.5M | ||
| Q2 25 | $497.1M | $176.3M | ||
| Q1 25 | $524.1M | $127.1M | ||
| Q4 24 | $497.5M | $174.0M | ||
| Q3 24 | $534.2M | $150.6M | ||
| Q2 24 | $575.7M | $480.7M | ||
| Q1 24 | $587.2M | $112.3M |
股东权益PAYORARE
| Q4 25 | $704.4M | $-80.0M | ||
| Q3 25 | $750.5M | $9.2M | ||
| Q2 25 | $770.9M | $151.3M | ||
| Q1 25 | $750.7M | $144.2M | ||
| Q4 24 | $724.8M | $255.0M | ||
| Q3 24 | $727.9M | $346.8M | ||
| Q2 24 | $669.4M | $432.4M | ||
| Q1 24 | $661.5M | $140.3M |
总资产PAYORARE
| Q4 25 | $9.0B | $1.5B | ||
| Q3 25 | $8.2B | $1.2B | ||
| Q2 25 | $8.1B | $1.3B | ||
| Q1 25 | $7.6B | $1.3B | ||
| Q4 24 | $7.9B | $1.5B | ||
| Q3 24 | $7.1B | $1.5B | ||
| Q2 24 | $6.9B | $1.6B | ||
| Q1 24 | $6.8B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $54.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $40.3M | $-100.8M |
| 自由现金流率自由现金流/营收 | 18.6% | -48.6% |
| 资本支出强度资本支出/营收 | 6.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.89× | — |
| 过去12个月自由现金流最近4个季度 | $206.6M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流PAYORARE
| Q4 25 | $54.9M | $-99.8M | ||
| Q3 25 | $54.2M | $-91.4M | ||
| Q2 25 | $70.7M | $-108.3M | ||
| Q1 25 | $53.7M | $-166.5M | ||
| Q4 24 | $45.9M | $-79.3M | ||
| Q3 24 | $50.1M | $-67.0M | ||
| Q2 24 | $41.4M | $-77.0M | ||
| Q1 24 | $39.5M | $-190.7M |
自由现金流PAYORARE
| Q4 25 | $40.3M | $-100.8M | ||
| Q3 25 | $49.2M | $-92.7M | ||
| Q2 25 | $68.1M | $-110.7M | ||
| Q1 25 | $49.0M | $-167.8M | ||
| Q4 24 | $42.1M | $-79.5M | ||
| Q3 24 | $48.5M | $-68.6M | ||
| Q2 24 | $40.2M | $-79.0M | ||
| Q1 24 | $37.9M | $-193.9M |
自由现金流率PAYORARE
| Q4 25 | 18.6% | -48.6% | ||
| Q3 25 | 23.5% | -58.0% | ||
| Q2 25 | 34.0% | -66.5% | ||
| Q1 25 | 26.3% | -120.5% | ||
| Q4 24 | 21.3% | -48.3% | ||
| Q3 24 | 26.9% | -49.2% | ||
| Q2 24 | 23.5% | -53.7% | ||
| Q1 24 | 23.6% | -178.2% |
资本支出强度PAYORARE
| Q4 25 | 6.7% | 0.5% | ||
| Q3 25 | 2.4% | 0.8% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 2.5% | 1.0% | ||
| Q4 24 | 1.9% | 0.1% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 0.7% | 1.4% | ||
| Q1 24 | 1.0% | 3.0% |
现金转化率PAYORARE
| Q4 25 | 2.89× | — | ||
| Q3 25 | 3.84× | — | ||
| Q2 25 | 3.63× | — | ||
| Q1 25 | 2.61× | — | ||
| Q4 24 | 2.52× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.28× | — | ||
| Q1 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PAYO
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
